Dashboard
1
The company is Net-Debt Free
- Poor long term growth as Operating profit has grown by an annual rate 7.73% of over the last 5 years
- The company is Net-Debt Free
- The company has been able to generate a Return on Equity (avg) of 14.48% signifying low profitability per unit of shareholders funds
2
Negative results in Mar 26
3
With ROE of 16.00%, it has a very expensive valuation with a 1.58 Price to Book Value
4
Below par performance in long term as well as near term
Stock DNA
Pharmaceuticals & Biotechnology
MXN 15,970 Million (Small Cap)
10.00
NA
0.00%
0.47
13.69%
1.36
Revenue and Profits:
Net Sales:
4,191 Million
(Quarterly Results - Mar 2026)
Net Profit:
495 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
1575.26%
0%
1575.26%
6 Months
1844.74%
0%
1844.74%
1 Year
1506.52%
0%
1506.52%
2 Years
1747.5%
0%
1747.5%
3 Years
933.57%
0%
933.57%
4 Years
1235.74%
0%
1235.74%
5 Years
1834.55%
0%
1834.55%
Genomma Lab Internacional SAB de CV for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
5.89%
EBIT Growth (5y)
7.73%
EBIT to Interest (avg)
3.31
Debt to EBITDA (avg)
1.32
Net Debt to Equity (avg)
0.44
Sales to Capital Employed (avg)
1.00
Tax Ratio
26.38%
Dividend Payout Ratio
48.39%
Pledged Shares
0
Institutional Holding
0.00%
ROCE (avg)
22.18%
ROE (avg)
14.48%
Valuation key factors
Factor
Value
P/E Ratio
10
Industry P/E
Price to Book Value
1.58
EV to EBIT
5.83
EV to EBITDA
5.27
EV to Capital Employed
1.40
EV to Sales
1.24
PEG Ratio
0.62
Dividend Yield
NA
ROCE (Latest)
23.98%
ROE (Latest)
16.00%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Mildly Bullish
Bearish
Dow Theory
Mildly Bearish
Mildly Bullish
OBV
No Trend
Mildly Bullish
Shareholding Snapshot : Jun 2018
Shareholding Compare (%holding) 
Majority shareholders
Foreign Institutions
Domestic Funds
Held in 0 Schemes (0%)
Foreign Institutions
Held by 1 Foreign Institutions (0.0%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Mar'26 - QoQ
Mar'26
Dec'25
Change(%)
Net Sales
4,190.60
4,017.00
4.32%
Operating Profit (PBDIT) excl Other Income
963.70
1,051.20
-8.32%
Interest
285.90
252.90
13.05%
Exceptional Items
0.00
0.00
Consolidate Net Profit
494.60
319.60
54.76%
Operating Profit Margin (Excl OI)
208.30%
214.40%
-0.61%
USD in Million.
Net Sales
QoQ Growth in quarter ended Mar 2026 is 4.32% vs -9.56% in Dec 2025
Consolidated Net Profit
QoQ Growth in quarter ended Mar 2026 is 54.76% vs -26.38% in Dec 2025
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
17,541.20
18,606.90
-5.73%
Operating Profit (PBDIT) excl Other Income
4,135.50
4,265.00
-3.04%
Interest
796.70
887.80
-10.26%
Exceptional Items
0.00
0.00
Consolidate Net Profit
1,614.00
2,091.10
-22.82%
Operating Profit Margin (Excl OI)
214.10%
209.90%
0.42%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is -5.73% vs 12.99% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is -22.82% vs 92.75% in Dec 2024
About Genomma Lab Internacional SAB de CV 
Genomma Lab Internacional SAB de CV
Pharmaceuticals & Biotechnology
Genomma Lab Internacional SAB de CV is a Mexico-based over-the-counter pharmaceutical (OTC pharmaceutical), generic drugs (GD) and personal care products company. The Company is engaged in the development, distribution and marketing of a range of products within different brands, for such treatments as anti-acne, varicose vein, hair loss, sexual stimulation and influenza; as well as analgesics and antifungals. The Company’s product portfolio includes such brands as Asepxia, Cicatricure, Goicoechea, Bengue, Diabet TX, Genoprazol, Goicotabs, Shot B, SilkaMedic, Siluet 40, Nikzon, X Ray, Next, Touch Me, Lomecan V and QG5, among others. The Company is a parent of a number of controlled entities, which have operations established in Mexico, the United States, Peru, Chile, Ecuador and Honduras, among others. In June 2014, the Company acquired 50% stake in Grupo Comercial e Industrial Marzam SA de CV.
Company Coordinates 
Company Details
Edificio Samara, Antonio Dovali Jaime no. 70 Piso 2, Colonia Santa Fe, MEXICO, D.F. None : 01210
Registrar Details






